Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): Results from a multicenter chart review

Supportive Care in Cancer

Volumn 20, Issue 9, 2012, Pages 2089-2096

  Henry, David H ^e   Langer, Corey J ^a   McKenzie, R Scott ^b   Piech, Catherine Tak ^b   Senbetta, Mekré ^b   Schulman, Kathy L ^c   Stepanski, Edward J ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Janssen Scientific Affairs LLC   (United States)

^c Healthcare   (United States)

^d ACORN Research LLC   (United States)

^e PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Chemotherapy induced anemia; Erythropoiesisstimulating agents; Hemoglobin; Transfusions

Indexed keywords

ANTIANEMIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

BLOOD TRANSFUSION; BREAST CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; COLORECTAL CANCER; CONFIDENCE INTERVAL; DATA EXTRACTION; DEMOGRAPHY; FEMALE; GOVERNMENT; HEALTH INSURANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MEDICARE; MULTIVARIATE ANALYSIS; NATIONAL COVERAGE DETERMINATION; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT DURATION;

AGED; ANEMIA; BLOOD TRANSFUSION; BREAST NEOPLASMS; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); COLORECTAL NEOPLASMS; ERYTHROPOIESIS; FEMALE; HEMOGLOBINS; HUMANS; INSURANCE COVERAGE; LUNG NEOPLASMS; MALE; MEDICAL AUDIT; MIDDLE AGED; NEOPLASMS; UNITED STATES;

EID: 84865159854     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1318-2     Document Type: Review

References (26)

1. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616-1634 (Pubitemid 29479929)
2. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293-2306 (Pubitemid 39348881)
3. Rodgers GM (2008) Managing patients with chemotherapyinduced anemia. Adv Stud Med 8:346-351
4. Feinberg B, Gilmore J, Gondesen T et al (2009) Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: results from a community oncology practice. Commun Oncol 6:257-261
5. Shord SS, Auerbach M (2009) Treating chemotherapy-induced anemia following the revised labeling for ESAs. Commun Oncol 6:279-282
6. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 111:25-41
7. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960-5972
8. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebocontrolled trial. Lancet 362:1255-1260 (Pubitemid 37324251)
9. Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ (2008) Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care. Pharmacotherapy 28:1S-15S (Pubitemid 351614774)
10. Smith RE Jr, Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA (2008) Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26:1040-1050
11. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, doubleblind, placebo-controlled study. Br J Haematol 122:394-403 (Pubitemid 36951623)
12. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027-1032 (Pubitemid 46596751)
13. Overgaard J, Hoff CM, Hansen HS et al (2007) Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)-the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer Suppl 5:6LB
14. Oncologic Drugs Advisory Committee briefing document: continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA. pdf. Accessed 15 March 2010
15. Background information for Oncologic Drugs Advisory Committee: safety of erythropoiesis-stimulating agents (ESAs) in oncology. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-01-01-Amgen.pdf. Accessed 15 March 2010
16. Decision memo for erythropoiesis-stimulating agents (ESAs) for nonrenal disease indications (CAG-00383N). The use of erythropoiesis stimulating agents in cancer and related neoplastic conditions. Available at http://www.cms.hhs. gov/mcd/viewdecisionmemo.asp? id=203. Accessed 15 March 2010
17. Information on erythropoiesis-stimulating agents (ESAs) epoetin alfa (marketed as Procrit, Epogen), darbepoetin alfa (marketed as Aranesp). Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm. Accessed 15 March 2010
18. Naeim A, Glaspy J (2008) Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007. J Clin Oncol 26:20595
19. Burton T, Larholt K, Apgar E et al (2008) Pre- vs. post-National Coverage Determination (NCD) blood utilization and hemoglobin values among Medicare patients treated with erythropoiesisstimulating agents (ESAs) for chemotherapy-induced anemia (CIA). In: American Society of Hematology, 50th Annual Meeting and Exposition, December 6-9, 2008, San Francisco, CA
20. Centocor Ortho Biotech Products, L.P. (2010) Procrit® (epoetin alfa) full prescribing information. Centocor ortho Biotech Products, LP, Raritan, NJ
21. Amgen Inc. (2010) Aranesp® (darbepoetin alfa) full prescribing information. Amgen Inc., Thousand Oaks, CA
22. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220 (Pubitemid 34993871)
23. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606-2617 (Pubitemid 46179449)
24. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA (2009) Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 27:2838-2847
25. Hulnick SA, Hess G, Hill J et al (2009) Erythropoiesis stimulating agent (ESA) administration at Hb <10 g/dL for chemotherapyinduced anemia (CIA) following the National Coverage Decision (NCD). J Clin Oncol 27:e20627
26. Shapira I, Raftopoulos H, Gralla RJ et al (2009) The impact of randomized trial results and altered regulatory policies on ESA use, transfusions, and thrombosis: a longitudinal analysis over a 3-year period of resource utilization data from a large comprehensive oncology program. J Clin Oncol 27:6611